Webinar | Direct-to-Biology, a powerful approach to accelerate hit finding: Concept and application to drug discovery programs

Presenters: Joe Mason, Associate Principal Scientist and Nick Bland, Group Leader

In the first of our Drug Discovery webinar series, we will be discussing Direct-to-Biology (D2B) and its potential to accelerate hit finding. The series is hosted by One Nucleus.

14.00-15.00 BST | Wednesday 9th October 2024 | Online

Direct-to-Biology (D2B) has emerged as a powerful method to find hit compounds and build Structure Activity Relationships (SAR) for drug discovery programs. During this webinar, we will cover the concept of D2B and how and when it can be applied to drug-discovery programs. A case study will be presented demonstrating the potential of this approach.

Agenda:
14.00 – 14.05: Introduction from One Nucleus and Domainex
14.05 – 14.45: Presentation from Joe Mason, Associate Principal Scientist and Nick Bland, Group Leader, Domainex
14.45 – 15.00: Q&A and Close

Register now or contact One Nucleus:
Phone: 01223 896450
Phone: 01223 896456
Email: info@onenucleus.com
Email: accounts@onenucleus.com